For decades, asbestos claims in the United States have hung over the John Crane Business like a long shadow. Now Smiths Group wants to hand that shadow to someone else. Alongside a set of annual numbers that beat City forecasts, the engineer said it has started a process to sell its legacy US asbestos liability.

Smiths Group (LSE:SMIN), a FTSE 100 constituent, published results for the year to 31 July 2026 on 22 September. Headline operating profit came in at £399m, ahead of the £388m analysts had expected. The shares rose more than 4% in early trading on the day as investors welcomed both the beat and the plan to shed a long-running liability.

A Leaner Smiths Delivers a Modest Beat

This was the first full set of numbers for a very different company. Over the past year, Smiths has sold Smiths Interconnect and Smiths Detection, in deals with a combined Enterprise value of £3.3bn. The disposals followed pressure from activist investor Engine Capital and leave Smiths as a more focused industrial technology group serving energy, industrial and construction customers.

Chief executive Roland Carter called 2026 "a year of significant strategic progress", saying the group had transformed its portfolio and unlocked more than £3bn of value. The remaining business is built around John Crane, which makes seals and filtration systems for the energy and process industries, and Flex-Tek, which makes heating and fluid-handling components.

The results also showed Smiths buying as well as selling. It acquired DRC Heat Transfer for £165m, a deal that adds exposure to data centres. It has also agreed £40m of sales of Flex-Tek industrial businesses.

Inside the Figures

Revenue rose 2.1% on a reported basis to £1,937m, from £1,898m, with organic growth of 1.2%. Headline operating profit increased from £388m to £399m, and the headline Operating Margin edged up to 20.6% from 20.5%. Headline Earnings Per Share rose to 86.8p from 81.9p.

Statutory figures were weaker, which is worth noting. Statutory operating profit fell to £289m from £347m, and statutory earnings per share dropped to 49.5p from 74.5p. Headline measures strip out items such as asbestos-related charges and restructuring, which explains much of the gap.

The divisions moved in different directions. John Crane grew 2.3% organically, helped by strong original equipment and Americas sales, despite a hit of about £20m linked to the conflict in the Middle East. Flex-Tek slipped 0.4% organically, as strong aerospace Demand was offset by lower construction and thermal solutions revenue.

Cash conversion was 96%, return on capital employed was 23.5%, and the group ended the year with net cash of £1,747m. The full-year Dividend rose 5.4% to 48.5p. Smiths said £1.5bn of share Buybacks had been completed, with a further £1.5bn authorised.

Why Selling the Asbestos Liability Could Change the Story

The asbestos claims date back many years and relate to products John Crane once sold in the US. They have long made the group harder to value, because the future cost of litigation is uncertain and charges can swing reported profits. The provision set aside for fiscal 2026 was £153m, down from £191m the previous year.

Smiths said a sale of the liability would bring Balance Sheet relief, higher free Cash Flow and less earnings volatility. Transfers of legacy liabilities to specialist buyers have become more common in recent years, as insurers and run-off firms look to take on long-tail risks for a price. If Smiths can agree a deal on acceptable terms, investors would be left with a simpler business built around seals, filtration and heat transfer.

Management also sounded more confident on growth. For the 2027 financial year it guided to organic Revenue growth of about 4% and a headline operating margin of about 21%. Smiths now expects to reach its medium-term target of 5% to 7% organic growth faster than previously expected, helped by data centres, energy market trends and changes to the Flex-Tek portfolio. The medium-term margin target is 21% to 23%.

What Could Still Go Wrong

The asbestos process is only at an early stage. There is no guarantee a buyer will be found, and any deal would come at a cost, since a buyer will want to be paid to take on an uncertain liability. The final price could disappoint the market if it is larger than expected, or reduce the cash available for returns.

Trading conditions also remain uneven. Management pointed to Supply chain disruption, volatile energy prices and weaker customer investment. The £20m hit at John Crane shows how exposed the business can be to events in the Middle East, and Flex-Tek's construction markets are sensitive to interest rates and housing activity.

There is also the question of what a smaller Smiths looks like. With Detection and Interconnect gone, the group is more concentrated, and the 1.2% organic growth achieved in 2026 is well short of the 4% now guided for next year. Delivering that step-up will require the data centre and energy opportunities to translate into orders. The gap between headline and statutory profit also means investors will keep a close eye on the costs that sit outside the headline figures.

The Next Milestones for Smiths

The most important item to watch is progress on the asbestos sale, including who might buy the liability and on what terms. Any update on the timetable is likely to draw close attention from shareholders.

The pace of the remaining buyback will also matter, as will early signs of how DRC Heat Transfer is performing and whether its data centre exposure lifts orders as management hopes. Smiths usually holds its Annual General Meeting in November, often with a trading update, which would be the first chance to check progress against the 4% growth guidance. Half-year results would follow in the spring.

Conclusion

Smiths delivered a modest profit beat, raised its dividend and set out a plan that could remove one of its longest-running problems. The share price reaction suggests investors like the direction of travel. However, organic growth was slim in 2026, statutory profit fell, and the asbestos sale still has to be agreed. The next year will show whether a leaner Smiths can turn its promises into faster growth.